15 results
8-K
EVOK
Evoke Pharma Inc
13 Jan 21
Results of Operations and Financial Condition
4:02pm
were captured. Survey respondents were split into three groups drawn from the healthcare practitioner (“HCP”) community; “target” gastroenterologists
8-K
EX-99.1
EVOK
Evoke Pharma Inc
10 Aug 23
Evoke Pharma Reports Second Quarter 2023 Financial Results
9:03am
community, healthcare providers, patients, and investors on the significance of our healthcare resource utilization data has only just begun. Across the board
8-K
EX-99.1
EVOK
Evoke Pharma Inc
9 Nov 23
Evoke Pharma Reports Third Quarter 2023 Financial Results
9:00am
the gastroenterology community a resulting cost savings of $15,000 per patient in their first 6 months of GIMOTI treatment that underscores the financial
8-K
EX-10.2
EVOK
Evoke Pharma Inc
11 May 23
Departure of Directors or Certain Officers
4:00pm
and resides in a community property state, a designation of a person other than the Participant’s spouse as his or her beneficiary shall not be effective
8-K
EX-10.1
EVOK
Evoke Pharma Inc
11 May 23
Departure of Directors or Certain Officers
4:00pm
in a domestic partnership qualified under Applicable Law and resides in a community property state, a designation of a person other than the Holder’s
424B4
uxsz108n
9 Feb 24
Prospectus supplement with pricing info
5:14pm
424B3
pay76a
14 Mar 24
Prospectus supplement
6:44pm
- Prev
- 1
- Next